Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential health impacts of Opzelura for patients on the treatment of vitiligo and eczema.

Opzelura (ruxolitinib), is currently not approved by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has noted that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for this on the 23 of February 2023 and is currently pending European Commission (EC) approval.

Should an application for Opzelura be received by the MHRA, we have processes in place to review this and, if appropriate, issue a licence in line with an EC decision.